Retatrutide and trizepatide represent a recent class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists https://elijaheuau605038.blogaritma.com/36724249/recent-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide